Thrombophilia Profile Interpretation
Use
Interpretation of testing performed as part of a profile to evaluate patients with thrombosis or hypercoagulability states including detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis, detecting a deficiency of antithrombin, protein C, or protein S, detecting activated protein C resistance (and the factor V R506Q [Leiden] mutation if indicated), and detecting the prothrombin G20210A mutation.
Special Instructions
Only orderable as part of a profile. For more information see AATHR / Thrombophilia Profile, Plasma.
Limitations
Thrombophilia testing is best performed in medically stable patients who are not receiving oral vitamin K inhibitor (eg, warfarin, Coumadin), heparin, low-molecular-weight heparin, hirudin (Refludan), argatroban, fibrinolytic agents (eg, streptokinase, tissue plasminogen activator), or platelet GPIIbIIIa (alpha IIb beta3) inhibitors (abxicimab [ReoPro], tirofiban, aggrastat). However, useful information can be obtained in patients receiving anticoagulation therapy.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 69049-5
- 69049-5
- 18771-6
Result Turnaround Time
4-7 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Container
Na Cit
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |